Back to the previous page

SwissNeuroRehab, a new Model of Digital Neurorehabilitation along the Continuum of Care


Funding Agency: InnoSuisse

Duration: 2022-2026

Partners: CHUV, Inselspital Bern, HUG, University Hospital Zurich, Neurorestore (EPFL), ETH, U. Bern, Institute de Santé Globale (Université de Genève), Unisanté, HEIG-VD, MindMaze SA, HOCOMA AG, Onward Medical SA, Myoswiss AG, Lambda Health System SA, Swiss Rehabilitation, Fondation EMS Le Marronnier, Physio Clinics SA, Association CARA, Pryv SA, PLATEFORME-REHA.CH, Espace Compétences SA, MEDICOL Sarl,Institution de Lavigny, Clinique romande de réadaptation Sion, Kliniken Valens, Rehaklinik Bellikon, Rehaklinik Zihlschlacht

SwissNeuroRehab is a research project funded by Innosuisse. Developed and coordinated by the CHUV, SwissNeuroRehab is the archetype of interdisciplinary projects. Through its vision, it is setting up an innovative model of neurological rehabilitation. The overall budget of the project is 11.2 million Swiss francs over five years, including 5.9 million from Innosuisse’s Flagship programme and the rest by the industrial partners. Thanks to this significant financial support, a consortium bringing together the main academic, clinical and industrial players in Switzerland is working to combine conventional neurorehabilitation approaches with new digital technologies, to offer personalized care to patients with sequelae of cerebrovascular accidents (stroke), head trauma and paraplegia.

SwissNeuroRehab will develop and validate an effective and efficient model of neurorehabilitation along the continuum of care in Switzerland. This patient-centered model will specify the clinical, operational and economic needs to treat sensorimotor and cognitive deficits after stroke, traumatic brain injury and spinal cord injury. State-of-the-art, evidence-based therapeutic programs, leveraged by Digital Therapies, will be validated and implemented into the clinical routine by Swiss centres of excellence. An inter-cantonal economic model will validate the  reimbursement of the new model within the healthcare system and estimate the return of investment for healthcare providers and MedTech companies. Novel programs for education and dissemination will be built for healthcare professionals, decision makers, patients and caregivers. The model will offer a long-term solution to address the challenges due to the increasing prevalence of neurological disorders in the ageing society.